Effect of peripheral blood progenitor cell dose on hematopoietic recovery: Identification of minimal progenitor cell requirements for rapid engraftment

Bone Marrow Transplantation

Volumn 33, Issue 6, 2004, Pages 589-595

  Miyamoto, T ^a   Shinozuka, T ^a   Maeda, H ^a   Hirasawa, T ^a   Muramatsu, T ^a   Murakami, M ^a   Makino, T ^a   Itagaki, H ^a   Nakamura, Y ^a  

^a TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

CD34 + cell; Hematopoietic reconstruction; Minimum threshold of CFU GM; Multicycle HDC; PBSCT

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ARTICLE; BONE MARROW BIOPSY; CALCULATION; CANCER PATIENT; CLINICAL ARTICLE; COLONY FORMING UNIT GM; CONTROLLED STUDY; CRYOPRESERVATION; DRUG MEGADOSE; FEMALE; HEMATOPOIETIC SYSTEM; HUMAN; HUMAN CELL; LEUKOCYTE; OVARY CANCER; PERIPHERAL BLOOD STEM CELL; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; THROMBOCYTE;

FEMALE; HEMATOPOIETIC STEM CELLS; HUMANS; LEUKOCYTE COUNT; OVARIAN NEOPLASMS; PLATELET COUNT; PLATELET TRANSFUSION; RETROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS;

EID: 1842483157     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704412     Document Type: Article

References (34)

1. Shinozuka T, Murakami M, Miyamoto T et al. High-dose chemotherapy (HDC) with autologous bone marrow transplantation (ABMT) in ovarian cancer [abstract]. Proc Am Soc Clin Oncol 1991; 10: 193.
2. Shinozuka T, Miyamoto T, Muramatsu T et al. Long-term follow-up and prognostic analysis in epithelial ovarian cancer treated by high-dose cyclophosphamide, adriamycin and cisplatin (CAP) with autologous bone marrow transplantation (ABMT) [abstract]. Proc Am Soc Clin Oncol 1997; 16: 378a.
3. Shinozuka T, Hirasawa T, Muramatsu T et al. Long-term results of high dose chemotherapy (HDC) with hematopoietic stem cell support in patients with epithelial ovarian cancer [abstract]. Proc Am Soc Clin Oncol 1998; 17: 375a.
4. Shinozuka T, Miyamoto T, Muramatsu T et al. High dose chemotherapy with autologous stem cell support in the treatment of patients with ovarian carcinoma. Cancer 1999; 85: 1555-1564.
5. Shinozuka T, Muramatsu. T, Miyamoto T et al. Long-term results and prognostic analysis in advanced and recurrent/ refractory epithelial ovarian cancer treated by high-dose cyclophosphamide, adriamycin, and cisplatin with autologous bone marrow transplantation. Int J Clin Oncol 1999; 4: 273-279.
6. Morgan MA, Stadtmauer EA, Luger SM et al. Cycles of dose-intensive chemotherapy with peripheral stem cell support in persistent or recurrent platinum-sensitive ovarian cancer. Gynecol Oncol 1997; 67: 272-276.
7. Fennelly DW, Aghajanian C, Shapiro F et al. Dose escalation of paclitaxel with high-dose carboplatin using peripheral blood progenitor cell support in patients with advanced ovarian cancer. Semin Oncol 1997; 24: S2-26-S2-30.
8. Wandt H, Birkmann J, Schaefer-Eckart K et al. Sequential cycles of high-dose chemotherapy supported by G-CSF (filgrastim)-mobilized peripheral blood progenitor cells (PBPC) in advanced ovarian cancer: A phase I/II dose escalation study for carboplatin. Proc Am Soc Clin Oncol 1997; 16: 92a.
9. Schilder RJ, Shea TC. Multiple cycles of high-dose chemotherapy for ovarian cancer. Semin Oncol 1998; 25: 349-355.
10. Aghajanian C, Fennelly D, Shapiro F et al. Phase II study of 'dose dense' high-dose chemotherapy treatment with peripheral-blood progenitor-cell support as primary treatment for patients with advanced ovarian cancer. J Clin Oncol 1998; 16: 1852-1860.
11. Hogge DE, Lambie K, Sutherland HJ et al. Quantitation of primitive and lineage-committed progenitors in mobilized peripheral blood for prediction of platelet recovery post autologous transplant. Bone Marrow Transplant 2000; 25: 589-598.
12. Weaver CH, Hazelton B, Birch R et al. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood 1995, 3961-3969.
13. + cells for autologous stem cell transplantation significantly reduces febrile complications and use of antibiotics after transplantation. Bone Marrow Transplant 1999; 23: 1177-1181.
14. + cell counts decrease hematologic toxicity of autologous peripheral blood progenitor cell transplantation. Blood 1998; 91: 3148-3155.
15. Tricot G, Jagannath S, Vesole D et al. Peripheral blood stem cell transplants for multiple myeloma: Identification of favorable variables for rapid engraftment in 225 patients. Blood 1995; 85: 588-596.
16. - cells influence days to engraftment and transfusion requirements in autologous blood stem cell recipients. J Clin Oncol 1998; 16: 2093-2104.
17. Lowenthal RM, Faberes C, Marit G et al. Factors influencing haematopoietic recovery following chemotherapy-mobilised autologous peripheral blood progenitor cell transplantation for haematological malignancies: A retrospective analysis of a 10-year single institution experience. Bone Marrow Transplant 1998; 22: 763-770.
18. Gilmore MJML, Prentice HG, Blacklock HA et al. A technique for rapid isolation of bone marrow mononuclear cells using Ficoll-Metrizoate and IBM 2991 blood cell processor. Br J Haematol 1982; 50: 619-626.
19. Wunder E, Sovalat H, Fritsch G et al. Report on the European workshop on peripheral blood stem cell determination and standardization - Mulhouse, France, February 6-8 and 14-15, 1992. J Hematother 1992; 1: 131-142.
20. Legros M, Dauplat J, Fleury J et al. High-dose chemotherapy with hematopoietic rescue in patients with stage III to IV ovarian cancer: Long term results. J Clin Oncol 1997; 15: 1302-1308.
21. Bertucci F, Viens P, Gravis G et al. High-dose chemotherapy with hematopoietic stem cell support in patients with advanced epithelial ovarian cancer: Analysis of 67 patients treated in a single institution. Anticancer Res 1999; 19: 1455-1462.
22. Ledermann JA, Herd R, Maraninchi D et al. High dose chemotherapy in ovarian cancer: An analysis of experience of the European Group for blood and marrow transplant (EBMT) over 7 years. Proc Am Soc Clin Oncol 1999; 18: 360a.
23. Thigpen JT. Dose-intensity in ovarian carcinoma: Hold, enough? J Clin Oncol 1997; 15: 1291-1293.
24. Cure H, Battista C, Guastalla J et al. Phase III randomized trial of high dose chemotherapy (HDC) and peripheral blood stem cell (PBSC) support as consolidation in patients (pts) with responsive low-burden advanced ovarian cancer (ADC): Preliminary results of a GINECO/FNCLCC/SFGM-TC study. Proc Am Soc Clin Oncol 2001; 20: 204a.
25. Beyer J, Schwella N, Zingsem J et al. Hematopoietic rescue after high dose chemotherapy using autologous peripheral-blood progenitor cells or bone marrow: A randomized comparison. J Clin Oncol 1995; 13: 1328-1335.
26. To LB, Roberts MM, Haylock DN et al. Comparison of haematological recovery times and supportive care requirements of autologous recovery phase peripheral blood stem cell transplants, autologous bone marrow transplants and allogeneic bone marrow transplants. Bone Marrow Transplant 1992; 9: 277-284.
27. Bender JG, To LB, Williams S et al. Defining a therapeutic dose of peripheral blood stem cells. J Hematother 1992; 1: 329-341.
28. + peripheral blood progenitor cell dose on hematopoietic recovery. Biol Blood Marrow Transplant 1998; 4: 84-92.
29. Gandhi MK, Jestice K, Scott MA et al. The minimum CD34 threshold depends on prior chemotherapy in autologous peripheral blood stem cell recipients. Bone Marrow Transplant 1999; 23: 9-13.
30. To LB, Haylock DN, Dyson PG et al. An unusual pattern of hematopoietic reconstitution in patients with acute myeloid leukemia transplanted with autologous recovery phase peripheral blood. Bone Marrow Transplant 1990; 6: 109-114.
31. Perez-Simon JA, Caballero MD, Corral M et al. Minimal number of circulating CD34+ cells to ensure successful leukapheresis and engraftment in autologous peripheral blood progenitor cell transplantation. Transfusion 1998; 38: 385-391.
32. + cell dose in long-term engraftment following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 1999; 24: 1279-1283.
33. Brandt J, Baird N, Lu L et al. Characterization of a human hematopoietic progenitor cell capable of forming blast cell containing colonies in vitro. J Clin Invest 1998; 82: 1017-1027.
34. Krause DS, Fackler MJ, Civin CI et al. CD34: Structure, biology, and clinical utility. Blood 1996; 87: 1-13.